Ophthalmic Suspension Market Size was valued at USD 2.87 Billion in 2023. The Global Ophthalmic Suspension industry is projected to grow from USD 3.43 Billion in 2024 to USD 7.11 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.23% during the forecast period (2024 - 2032).
The interruption in the form of applied to treat eye infections and related symptoms is commonly termed ophthalmic suspension. Commonly it is used in a combination of two such as antibiotics and a corticosteroid for more advanced treatment. Several bacterial eye infections such as conjunctivitis are treated by the ophthalmic suspension.
The growing generality of eye diseases across the world is one of the main elements contributing to the rise of the ophthalmic suspension market. However, the rising geriatric population which is the most common eye disorder, and the increasing number of bacterial infection cases in children will also drive the growth of the market. However, according to the world health organization (WHO), GLAUCOMA is the second main cause of blindness around the globe which will rise the ophthalmic suspension market growth. On the other side, the side effects of ophthalmic suspension may degrade the market growth during the anticipated period.
The ophthalmic suspension market is segmented on the basis of type of content, which is segmented into antibiotic, antifungal, antibacterial, steroids, NSAIDs (non-steroidal anti-inflammatory drugs) and others.
On the basis of applications, it is segmented into bacterial infections, retinal disorders, glaucoma, allergies, diabetic eye disease, and others. Bacterial infection is further conjunctivitis, scleritis, and others. Retinal disorder is further segmented into macular degeneration, branch retinal vein occlusion, central retinal vein occlusion, congenital x-linked retinoschisis, and others.
On the basis of end user, the Ophthalmic Suspension Market is segmented into hospitals, eye clinics, pharmacies, and others.
Some of the key players in this market are:
The American region accounted for the largest share of the ophthalmic suspension market due to increasing prevalence of eye related diseases and increasing demand for new ophthalmic suspension for its treatment. Moreover, increasing geriatric population is another major factor responsible for the market growth in American countries.
Europe is the second largest ophthalmic suspension market across the globe owing to increasing awareness regarding eye related diseases, growing technological advancements in healthcare domain and increasing investment in healthcare domain by government.
In Asia Pacific, increasing government support for research & development in healthcare domain, growing number of ophthalmic clinics, and increasing prevalence of eye related diseases drives the growth of the market in this region.
The Middle East & Africa is expected to show a least market share due to less availability of medical facilities, and less development in healthcare domain.
The report on the ophthalmic suspension market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.
Recent Development
According to the world health organization (WHO), the ophthalmic suspension market around the globe is projected to grow at a compound annual growth rate of 6.80% during the anticipated period of 2024 to 2032. The market for ophthalmic suspension is categorized or classified on the basis of type of content, which is further segmented into antibiotics, antifungal, antibacterial, steroids, and others.
Based on applications the market has been again divided into bacterial infections, retinal disorders, allergies, glaucoma, diabetic eye disease, and others. On the other hand on the basis of the end-user, the ophthalmic suspension market is further divided into hospitals, eye clinics, pharmacies, and others. The American region accounted for the widest share of the ophthalmic suspension market due to the rising generality of eye-related diseases and the increasing ultimatum for new ophthalmic suspension for its treatment. However, increasing population is another primary factor for the market growth.
Intended Audience
| Attribute/Metric | Details |
| Market Size 2023 | 2.87 (USD Billion) |
| Market Size 2024 | 3.43 (USD Billion) |
| Market Size 2032 | 7.11 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 11.23 % (2024 - 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2023 |
| Market Forecast Period | 2024 - 2032 |
| Historical Data | 2019 - 2023 |
| Â Â Geographies Covered | Â Â Â America, Europe, Asia Pacific, Middle East & Africa |
| Â Â Key Vendors | Â Â Novartis AG (Alcon), ALLERGAN, Pfizer Inc., Merck & Co., Inc., Bausch & Lomb Incorporated, Falcon Group, Valeant, Bayer AG, and Genentech, Inc. |
| Â Â Key Market Opportunities | Â Â Increasing demand for new ophthalmic suspension, growing technological advancements in healthcare and increasing investment |
| Â Â Key Market Drivers | Â Â Growing generality of eye diseases, rising geriatric population and increasing number of bacterial infection cases in children |
Ophthalmic Suspension Market Highlights:
Frequently Asked Questions (FAQ) :
Ophthalmic suspension market can expand at 11.23% CAGR from 2024 to 2032.
High prevalence of eye diseases is the biggest driver of the global ophthalmic suspension market.
Adverse effects of ophthalmic suspension can impede the growth of the global ophthalmic suspension market.
The Americas can dominate the global ophthalmic suspension market till 2032 owing to high prevalence of eye diseases.
Genentech, Inc., Valeant, ALLERGAN, Pfizer Inc., Merck & Co., Inc., Bausch & Lomb Incorporated, Falcon Group, Bayer AG, and Novartis AG (Alcon) are notable players of the global ophthalmic suspension market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
